Rezera files for IPO to back NLRP3 work in peripheral artery disease
Rezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts. The biotech submitted its pitch Wednesday ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
